NCI-sponsored phase II study of [18f]fluoroestradiol (FES) as a marker of hormone sensitivity of metastatic breast cancer: Initial results

被引：2
|
作者：
Mankoff, D. A.
Linden, H. M.
Link, J.
Kurland, B. F.
Schubert, E. K.
Peterson, L.
Gadi, V. K.
Specht, J. M.
Shankar, L.
Eary, J. F.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
[4] NCI, Canc Imaging Program, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11104
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Progression-free survival assessment to second line hormone therapy by pretherapeutic [18F]-FDG and [18F]-FES PET-CT in positive estrogen receptors metastatic breast cancer patients: preliminary results.
    Maucherat, Bruno
    Campion, Loic
    Le Duc-Pennec, Alexandra
    Girault, Sylvie
    Alberini, Jean-Louis
    Ferrer, Ludovic
    Allam, Nadia
    Bodere, Francoise
    Bouvet, Yann
    Rousseau, Caroline
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [32] NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3'-Deoxy-3'-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies
    Spence, Alexander M.
    Muzi, Mark
    Link, Jeanne M.
    O'Sullivan, Finbarr
    Eary, Janet F.
    Hoffman, John M.
    Shankar, Lalitha K.
    Krohn, Kenneth A.
    MOLECULAR IMAGING AND BIOLOGY, 2009, 11 (05) : 343 - 355
  • [33] [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER plus Breast Cancer Undergoing Treatment with Rintodestrant
    Iqbal, Ramsha
    Yaqub, Maqsood
    Bektas, Huseyyin O.
    Oprea-Lager, Daniela E.
    de Vries, Elisabeth G. E.
    Glaudemans, Andor W. J. M.
    Aftimos, Philippe
    Gebhart, Geraldine
    Beelen, Andrew P.
    Schuit, Robert C.
    Windhorst, Albert D.
    Boellaard, Ronald
    van Oordt, C. Willemien Menke-van der Houven
    CLINICAL CANCER RESEARCH, 2023, 29 (11) : 2075 - 2084
  • [34] The Preliminary Study of 16α-[18F] fluoroestradiol PET/CT in Assisting the Individualized Treatment Decisions of Breast Cancer Patients
    Sun, Yifei
    Yang, Zhongyi
    Zhang, Yongping
    Xue, Jing
    Wang, Mingwei
    Shi, Wei
    Zhu, Beiling
    Hu, Silong
    Yao, Zhifeng
    Pan, Herong
    Zhang, Yingjian
    PLOS ONE, 2015, 10 (01):
  • [35] Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET
    Gennari, A.
    Brain, E.
    De Censi, A.
    Nanni, O.
    Wuerstlein, R.
    Frassoldati, A.
    Cortes, J.
    Rossi, V.
    Palleschi, M.
    Alberini, J. L.
    Matteucci, F.
    Piccardo, A.
    Sacchetti, G.
    Ilhan, H.
    D'Avanzo, F.
    Ruffilli, B.
    Nardin, S.
    Monti, M.
    Puntoni, M.
    Fontana, V.
    Boni, L.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2024, 35 (06) : 549 - 558
  • [36] The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review
    Katzenellenbogen, John A.
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 92 : 24 - 37
  • [37] Dynamic whole-body [18F]FES PET/CT increases lesion visibility in patients with metastatic breast cancer
    Pedersen, Mette A.
    Munk, Ole L.
    Dias, Andre H.
    Steffensen, Johanne H.
    Moller, Anders L.
    Johnsson, Anna Lyhne
    Hansen, Kim Vang
    Bender, Dirk
    Jakobsen, Steen
    Busk, Morten
    Gormsen, Lars C.
    Tramm, Trine
    Borgquist, Signe
    Vendelbo, Mikkel H.
    EJNMMI RESEARCH, 2024, 14 (01)
  • [38] Dynamic whole-body [18F]FES PET/CT increases lesion visibility in patients with metastatic breast cancer
    Mette A. Pedersen
    Ole L. Munk
    André H. Dias
    Johanne H. Steffensen
    Anders L. Møller
    Anna Lyhne Johnsson
    Kim Vang Hansen
    Dirk Bender
    Steen Jakobsen
    Morten Busk
    Lars C. Gormsen
    Trine Tramm
    Signe Borgquist
    Mikkel H. Vendelbo
    EJNMMI Research, 14
  • [39] Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
    Hudis, CA
    Seidman, AD
    Crown, JPA
    Balmaceda, C
    Freilich, R
    Gilewski, TA
    Hakes, TB
    Currie, V
    Lebwohl, DE
    Baselga, J
    Raptis, G
    Gollub, M
    Robles, M
    Bruno, R
    Norton, L
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 58 - 65
  • [40] Value of [18F]-FES-PET to solve clinical dilemmas in breast cancer patients: A retrospective study
    Boers, Jorianne
    Loudini, Naila
    Brunsch, Celina L.
    Koza, Sylvia A.
    de Vries, Erik F. J.
    Glaudemans, Andor W. J. M.
    Hospers, Geke A. P.
    Schroder, Carolina P.
    CANCER RESEARCH, 2021, 81 (04)
12345